Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioblastoma 39Melanoma 34Gliosarcoma 34Brain Neoplasms 33Breast Neoplasms 31Lymphoma 24Neoplasm Metastasis 23Astrocytoma 23Colonic Neoplasms 20Multiple Myeloma 19Leukemia, Myeloid, Acute 19Leukemia 19Carcinoma, Non-Small-Cell Lung 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 18Colorectal Neoplasms 18Central Nervous System Neoplasms 18Carcinoma, Renal Cell 18Rectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 16Squamous Cell Carcinoma of Head and Neck 15Oligodendroglioma 15Pancreatic Neoplasms 14Myelodysplastic Syndromes 14Lung Neoplasms 14Sarcoma 13

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡